Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 1

红细胞输注同种免疫的基本和转化机制。

基本信息

  • 批准号:
    10711668
  • 负责人:
  • 金额:
    $ 40.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-10 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Humoral immunization to alloantigens on red blood cells (RBC alloimmunization) remains a major complication, and in some cases barrier to transfusion therapy for myriad diseases. However, the tendency to become alloimmunized is not evenly distributed; rather, patients tend to become alloimmunized to multiple alloantigens (responders) or none at all despite chronic transfusion (nonresponders). However, the factors that regulate responder vs. nonresponder status remain poorly defined. Rates of RBC alloimmunization is increased in patients with autoimmune pathologies, such as systemic lupus erythematosus (SLE). We have recently discovered that mice with SLE-like biology (i.e. develop anti-nuclear antibodies (ANAs)) have an increased rate of RBC alloimmunization. These mice develop ANAs due to a specific cluster of variant genes (NBA2) that contains multiple orthologues to human genes associated with SLE. Importantly, the NBA2 mice do not display organ pathology associated with SLE, leading to the hypothesis that ANA are an isolated component of SLE that affects RBC alloimmunization. Moreover, in NBA2 mice, toll like receptor 7 (TLR7) and TLR9 are known to regulate ANA formation through mutual antagonism (TLR7 promotes and TLR9 suppresses). These findings lead to the central hypothesis of this project: Central Hypothesis: Anti-nuclear antibodies cause increased RBC alloimmunization through activation of B cells as a result of dysregulated TLR7 and TLR9 signaling. This hypothesis is tested using a novel B cell receptor transgenic mouse that recognizes an authentic human blood group antigen (Kpb epitope) on the human KEL glycoprotein. The anti-Kpb mouse is combined with NBA2 mice that are then transfused with transgenic RBCs expressing the KEL-K2 variant of human KEL, which contains the Kpb antigen. This approach allows an in vivo mechanistic study of early activation and differentiation of naïve B cells specific for an RBC antigen on transfused RBCs. Specific aims 1 and 2 test the role of ANAs on RBC alloimmunization, including the manipulation of TLR7 and TLR9 signaling to rigorously test the central hypothesis. Specific aim 3 uses the human cohort of SCD patients studied in project 4. Patients with SCD have high rates of ANAs. The presence or absence of ANAs in patient plasma will be correlated with patterns of alloimmunization. Patient leukocytes will be stimulated in vitro, in the presence or absence of ANA containing plasma and/or TLR7 and TLR9 agonism or antagonism, using an assay that measures B cell activation and differentiation in response to CD4+ follicular T cell help. Synergy between projects comes from crosstalk between purinergic signaling (project 2) and TLR7 and TLR9, that reticulocytes (project 3) provide agonists for TLR7 and TLR9, and the prediction that genetic variations known to predispose humans to ANA formation will emerge as associations in the prospective GWAS study on RBC alloimmunization in patients with SCD (project 4). The proposed studies have the capacity to both identify novel predictors of RBC alloimmunization (i.e. ANAs) and to provide novel mechanistic insight that can serve as the basis for development of new therapeutics.
对红细胞上同种抗原的体液免疫(RBC同种免疫)仍然是一个主要的并发症, 并且在某些情况下阻碍了对多种疾病的输血治疗。然而, 同种免疫不是均匀分布的;相反,患者倾向于对多种同种抗原产生同种免疫 (应答者)或尽管慢性输血但根本没有(无应答者)。然而,调节的因素 应答者与非应答者状态仍然定义不清。RBC同种异体免疫率增加, 患有自身免疫性疾病的患者,如系统性红斑狼疮(SLE)。我们最近 发现具有SLE样生物学特征(即产生抗核抗体(ANA))的小鼠 RBC同种异体免疫这些小鼠由于一组特定的变异基因(NBA 2)而产生ANA, 含有与SLE相关的人类基因的多个直系同源物。重要的是,NBA 2小鼠不显示 与SLE相关的器官病理学,导致ANA是SLE的一个孤立组分的假设, 影响RBC同种免疫。此外,在NBA 2小鼠中,已知Toll样受体7(TLR 7)和TLR 9与Toll样受体7(TLR 7)和Toll样受体9(TLR 9)结合。 通过相互拮抗作用(TLR 7促进和TLR 9抑制)调节ANA形成。这些发现 导致本项目的中心假设:中心假设:抗核抗体导致红细胞增加 由于TLR 7和TLR 9信号传导失调,通过激活B细胞的同种异体免疫。这 使用识别真实人类血液的新型B细胞受体转基因小鼠来检验假设 组抗原(Kpb表位)的人KEL糖蛋白。将抗Kpb小鼠与NBA 2小鼠组合 然后用表达人KEL的KEL-K2变体的转基因RBC输注,所述变体含有 Kpb抗原。这种方法允许对幼稚B细胞的早期激活和分化进行体内机制研究。 对输注红细胞上的红细胞抗原具有特异性的细胞。具体目标1和2测试ANA对RBC的作用 同种异体免疫,包括操纵TLR 7和TLR 9信号传导,以严格测试中枢免疫。 假说.具体目标3使用项目4中研究的SCD患者的人类队列。SCD患者 有很高的ANA率。患者血浆中是否存在ANA将与模式相关 同种免疫患者白细胞将在体外刺激,在存在或不存在ANA的情况下, 血浆和/或TLR 7和TLR 9激动或拮抗作用,使用测量B细胞活化的测定, 分化响应于CD 4+滤泡T细胞的帮助。项目之间的协同作用来自于 嘌呤能信号传导(项目2)和TLR 7和TLR 9,网织红细胞(项目3)提供TLR 7的激动剂, TLR 9,以及已知使人类易患ANA形成的遗传变异的预测将出现, SCD患者RBC同种异体免疫的前瞻性GWAS研究中的相关性(项目4)。的 提出的研究有能力鉴定RBC同种免疫的新预测因子(即ANA), 提供了新的机制见解,可以作为新疗法开发的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES C. ZIMRING其他文献

JAMES C. ZIMRING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES C. ZIMRING', 18)}}的其他基金

Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion
红细胞输注同种免疫的基本机制和转化机制
  • 批准号:
    10711666
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
  • 批准号:
    10418747
  • 财政年份:
    2019
  • 资助金额:
    $ 40.29万
  • 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
  • 批准号:
    10192810
  • 财政年份:
    2019
  • 资助金额:
    $ 40.29万
  • 项目类别:
Immunobiology of Transfusion
输血免疫生物学
  • 批准号:
    10018077
  • 财政年份:
    2017
  • 资助金额:
    $ 40.29万
  • 项目类别:
Immunobiology of Transfusion
输血免疫生物学
  • 批准号:
    10192789
  • 财政年份:
    2017
  • 资助金额:
    $ 40.29万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10192790
  • 财政年份:
    2017
  • 资助金额:
    $ 40.29万
  • 项目类别:
Immunobiology of Transfusion
输血免疫生物学
  • 批准号:
    9360036
  • 财政年份:
    2017
  • 资助金额:
    $ 40.29万
  • 项目类别:
Antibody Mediated Immune Regulation
抗体介导的免疫调节
  • 批准号:
    10192792
  • 财政年份:
    2017
  • 资助金额:
    $ 40.29万
  • 项目类别:
Prevention of Platelet Alloimmunization by Costimulatory Blockade
通过共刺激阻断预防血小板同种免疫
  • 批准号:
    8783253
  • 财政年份:
    2014
  • 资助金额:
    $ 40.29万
  • 项目类别:
Prevention of Platelet Alloimmunization by Costimulatory Blockade
通过共刺激阻断预防血小板同种免疫
  • 批准号:
    9265120
  • 财政年份:
    2014
  • 资助金额:
    $ 40.29万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 40.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 40.29万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了